Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

This is a Phase I/II study evaluating safety and efficacy of proteasome inhibitor (bortezomib) in combination with CPX-351 (liposomal daunorubicin and cytarabine) for the treatment of newly-diagnosed TP53-mutated acute myeloid leukemia (TP53m AML). The primary endpoint of the study is to define safety/tolerability (phase I) and preliminary efficacy profile (phase II) of the treatment. The secondary endpoints of interest are complete remission (CR) rate, detectable minimal residual disease (MRD) status, overall response rate (ORR), rate of allogeneic hematopoietic cell transplantation (allo-HC

Trial Details

NCT ID
NCT07008638
Phase
PHASE1 / PHASE2
Sponsor
Masonic Cancer Center, University of Minnesota
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Bortezomib
  • CPX-351
Locations (sample)
  • Minneapolis, Minnesota, United States|44.97997,-93.26384

Key Eligibility Criteria

  • Adult (age ≥ 18 years at time of consent)
  • Have not received any systemic chemotherapy for the treatment of AML. Use of hydroxyurea and leukapheresis to control excess peripheral blasts is p…
  • Karnofsky performance status (KPS) ≥ 70
  • Adequate renal, hepatic and cardiac function defined as

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →